Regeneron, Sanofi to Restructure Collaboration for Kevzara, Praluent
December 10 2019 - 9:22AM
Dow Jones News
By Colin Kellaher
Regeneron Pharmaceuticals Inc. (REGN) and Sanofi SA (SAN.FR,
SNY) on Tuesday said they plan to restructure their collaboration
for Kevzara and Praluent into a royalty-based agreement.
Under the changes, France's Sanofi would gain sole global rights
to the rheumatoid-arthritis treatment Kevzara, along with sole
rights to the cholesterol drug Praluent outside the U.S.
Regeneron, based in Tarrytown, N.Y., would gain sole U.S. rights
to Praluent.
The companies said the move doesn't affect their collaboration
relating to the eczema and asthma treatment Dupixent, which Sanofi
Chief Executive Paul Hudson on Monday said "has the chance to be
one of the most successful medicines in the history of the
industry."
Sanofi and Regeneron said each company will be solely
responsible for funding development and commercialization expenses
in their respective territories under the changes, which they
expect to finalize in the first quarter.
Sanofi, which holds a 21.6% stake in Regeneron, on Monday said
it would stop investing in research into diabetes and
cardiovascular diseases as part of a broader strategic
overhaul.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 10, 2019 09:07 ET (14:07 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Oct 2023 to Oct 2024